BR112018012095A2 - formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina - Google Patents

formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina

Info

Publication number
BR112018012095A2
BR112018012095A2 BR112018012095A BR112018012095A BR112018012095A2 BR 112018012095 A2 BR112018012095 A2 BR 112018012095A2 BR 112018012095 A BR112018012095 A BR 112018012095A BR 112018012095 A BR112018012095 A BR 112018012095A BR 112018012095 A2 BR112018012095 A2 BR 112018012095A2
Authority
BR
Brazil
Prior art keywords
solid forms
phenylbenzo
isoquinolin
dihydro
substituted
Prior art date
Application number
BR112018012095A
Other languages
English (en)
Inventor
Bates Craig
P Reed David
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BR112018012095A2 publication Critical patent/BR112018012095A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a formas sólidas de dicloridrato de (r)-6-(2-fluorofenil)-n-(3-(2-(2-metoxietilamino)etil)fenil)-5,6-di-hidrobenzo[h]quinazolin-2-amina e métodos para preparação e uso das mesmas.
BR112018012095A 2015-12-17 2016-12-16 formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina BR112018012095A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268747P 2015-12-17 2015-12-17
PCT/US2016/067164 WO2017106642A1 (en) 2015-12-17 2016-12-16 Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds

Publications (1)

Publication Number Publication Date
BR112018012095A2 true BR112018012095A2 (pt) 2018-11-27

Family

ID=59057612

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012095A BR112018012095A2 (pt) 2015-12-17 2016-12-16 formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina

Country Status (19)

Country Link
US (3) US9981921B2 (pt)
EP (2) EP4019499A1 (pt)
JP (2) JP2018537499A (pt)
KR (1) KR20180086508A (pt)
CN (1) CN108368061A (pt)
AU (2) AU2016369523B2 (pt)
BR (1) BR112018012095A2 (pt)
CA (1) CA3006081A1 (pt)
EA (2) EA036295B1 (pt)
ES (1) ES2935818T3 (pt)
HK (1) HK1256825A1 (pt)
IL (1) IL259556B2 (pt)
MX (2) MX2018007414A (pt)
NZ (1) NZ742695A (pt)
PH (2) PH12018501246A1 (pt)
SA (1) SA518391805B1 (pt)
SG (1) SG11201804670PA (pt)
TW (2) TWI796250B (pt)
WO (1) WO2017106642A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018012325A2 (pt) 2015-12-17 2018-12-04 Arqule Inc métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
MX2018007414A (es) 2015-12-17 2018-11-09 Arqule Inc Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f¬]isoqui nolin-2-amina sustituidos.
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US7414140B2 (en) * 2003-06-18 2008-08-19 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
AU2007342007A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as Axl inhibitors
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
EP2643314B1 (en) * 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
US8815854B2 (en) * 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
US9802954B2 (en) * 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
EP2760859A1 (en) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Crystalline forms of azilsartan and preparation and uses thereof
BR112018012325A2 (pt) * 2015-12-17 2018-12-04 Arqule Inc métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
MX2018007414A (es) * 2015-12-17 2018-11-09 Arqule Inc Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f¬]isoqui nolin-2-amina sustituidos.
US9847831B2 (en) 2016-04-08 2017-12-19 Ciena Corporation Dual wavelenth optical time domain reflectometer systems and methods embedded in a WDM system

Also Published As

Publication number Publication date
SA518391805B1 (ar) 2022-12-21
EP4019499A1 (en) 2022-06-29
PH12018501246A1 (en) 2019-02-04
EP3390369A4 (en) 2019-08-14
ES2935818T3 (es) 2023-03-10
IL259556B2 (en) 2023-09-01
AU2016369523A1 (en) 2018-06-07
EP3390369B1 (en) 2022-11-02
CN108368061A (zh) 2018-08-03
AU2022201947A1 (en) 2022-04-14
US20180258055A1 (en) 2018-09-13
EA202091691A1 (ru) 2021-01-29
IL259556A (en) 2018-07-31
TW201736352A (zh) 2017-10-16
US9981921B2 (en) 2018-05-29
TWI771280B (zh) 2022-07-21
JP2018537499A (ja) 2018-12-20
MX2018007414A (es) 2018-11-09
HK1256825A1 (zh) 2019-10-04
MX2021000432A (es) 2022-07-28
IL259556B1 (en) 2023-05-01
EA036295B1 (ru) 2020-10-22
PH12020551465A1 (en) 2021-07-26
TW202241854A (zh) 2022-11-01
NZ742695A (en) 2022-10-28
KR20180086508A (ko) 2018-07-31
US20200002293A1 (en) 2020-01-02
JP2022031797A (ja) 2022-02-22
TWI796250B (zh) 2023-03-11
CA3006081A1 (en) 2017-06-22
US10227311B2 (en) 2019-03-12
US20170174636A1 (en) 2017-06-22
AU2016369523B2 (en) 2021-12-23
EA201891430A1 (ru) 2018-11-30
SG11201804670PA (en) 2018-07-30
AU2022201947B2 (en) 2023-07-27
WO2017106642A1 (en) 2017-06-22
EP3390369A1 (en) 2018-10-24
US10717710B2 (en) 2020-07-21

Similar Documents

Publication Publication Date Title
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
EP3181559B8 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
CL2016001895A1 (es) Compuestos
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
EA201692219A1 (ru) Способы получения противовирусных соединений
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
EP3389663A4 (en) PYRROLOPYRIMIDINE COMPOUNDS, USE AS LACKERS OF THE LRRK2 KINASE AND METHOD FOR THE PRODUCTION THEREOF
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
EP3307738A4 (en) ARYL-DIHYDRO-2H-BENZO [B] [1,4] OXAZINE-SULPHONAMIDE AND RELATED COMPOUNDS FOR USE AS AGENTS OF RORY AND FOR THE TREATMENT OF DISEASES
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
EP3292119A4 (en) DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
PH12019550235A1 (en) Kinase inhibitors and uses thereof
DK3412673T3 (da) Fremgangsmåde til fremstilling af pyrrolo[3,2-D]pyrimidin-forbindelse og mellemprodukter deraf
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
DK3251523T3 (da) Fremgangsmåde til fremstilling af granuleret tilskudsfoder
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
EP3448852A4 (en) NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
IL250025A0 (en) Novel 5,2-disubstituted pyrimidines as pde inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements